Earnings Call · Q1 FY2023·2023-05-14

Q1 23EPS -14.29%·Rev n/aQ4 22EPS -16.67%·Rev n/aQ3 22EPS +84.78%·Rev n/aQ2 22EPS +84.72%·Rev n/a⚠ consensus missing

Chemomab Therapeutics Ltd. CMMB

Barbara Lindheim — Consulting Vice President of Strategic Communications

Dale Pfost — Chairman and CEO

Adi Mor — Unknown

Matt Frankel — Unknown

Don Marvin — CFO, Chief Operating Officer and Executive Vice President

−1.5%1d on move date−1.4% vs SPY3d−0.6%5d+9.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more CMMB calls or request research access.

More CMMB calls Browse calls Request research access